Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vitiligo Vulgaris Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Stress Response Pathways in Vitiligo

NCT02797574
View directory record Official record
Conditions
Vitiligo
Interventions
Punch Biopsy at a Lesional Site, Punch Biopsy at a Non- Lesional site
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

NCT05298033
View directory record Official record
Conditions
Vitiligo
Interventions
Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy, Sham phototherapy, Vehicle
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

NCT05750823
View directory record Official record
Conditions
Nonsegmental Vitiligo With Genital Involvement
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Fremont, California • Los Angeles, California • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

NCT05247489
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% cream, NB-UVB phototherapy
Drug · Device
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Fountain Valley, California • Sacramento, California • Sunnyvale, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1 Interventional

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

NCT02281058
View directory record Official record
Conditions
Vitiligo
Interventions
Abatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
GIA632, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib for the Treatment of Vitiligo

NCT02809976
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% Phosphate Cream
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Examination Of Vitiligo Skin Samples Before and After UVB Treatment

NCT00177034
View directory record Official record
Conditions
Vitiligo
Interventions
Narrow Band UVB Treatment
Drug
Lead sponsor
Mimi Cho, MD
Individual
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2Phase 3 Interventional

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

NCT02191748
View directory record Official record
Conditions
Vitiligo
Interventions
Needling, Triamcinolone
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

NCT00367224
View directory record Official record
Conditions
Vitiligo
Interventions
6 to 9 ultraviolet B treatments, Skin biopsies
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

NCT05971381
View directory record Official record
Conditions
Vitiligo
Interventions
RECELL® Autologous Cell Harvesting Device
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo

NCT00134368
View directory record Official record
Conditions
Vitiligo
Interventions
Etanercept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters

NCT05256147
View directory record Official record
Conditions
Vitiligo
Interventions
Ibuprofen
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Vitiligo Skin Transplantation

NCT00830713
View directory record Official record
Conditions
Vitiligo
Interventions
Melanocyte-keratinocyte transplantation procedure (MKTP)
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

NCT06113328
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
MK-6194, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional

Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions

NCT04271501
View directory record Official record
Conditions
Vitiligo
Interventions
Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB), RECELL 1:5 and Ultraviolet Lamp (UVB), RECELL 1:10 and Ultraviolet Lamp (UVB), RECELL 1:20 and Ultraviolet Lamp (UVB)
Procedure · Device
Lead sponsor
Avita Medical
Industry
Eligibility
22 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

NCT04487860
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
AS012, Placebo
Drug
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not yet recruiting No phase listed Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169
View directory record Official record
Conditions
Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
2,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

NB-UVB and PUVA Vitiligo Study

NCT01732965
View directory record Official record
Conditions
Vitiligo
Interventions
Phototherapy, Phototherapy and Photochemotherapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

NCT04374435
View directory record Official record
Conditions
Vitiligo
Interventions
MKTP with Surgical blade, MKTP with Negative Pressure Instrument, Suction blister grafting without cell dissociation
Procedure · Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Gut and Skin Microbiome in Vitiligo Disease Progression

NCT03577327
View directory record Official record
Conditions
Vitiligo, Healthy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 5:15 AM EDT